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Abstract The purpose of this study was to assess the fea-
sibility of sentinel lymph node (SLN) biopsy in thyroid
neoplasms. Ten patients with uninodular thyroid disease
and no evidence of lymph node metastases were exam-
ined. Lymph node mapping was performed by preopera-
tive lymphoscintigraphy and intraoperative use of a hand-
held gammaprobe. Following thyroidectomy, the SLN(s)
were selectively excised and worked-up histologically for
occult metastases. Overall detection of SLNs was possible
in 50% of the cases with lymphoscintigraphy and in 100%
with the gammaprobe. All SLNs in the lateral compartment
and upper mediastinum were accurately detected with lym-
phoscintigraphy. One patient with a papillary carcinoma
showed a metastasis in the SLN. One patient experienced
temporary lesion of the recurrent laryngeal nerve. In con-
clusion, sentinel lymph node biopsy is technically feasible.
The combination of lymphoscintigraphy and gammaprobe
accurately reveals SLNs in the central and lateral com-
partment and in the mediastinum. Search for SLNs in the
lower central compartment enhances the risk of injuring
the recurrent laryngeal nerve. The clinical relevance of
SLN biopsy in papillary thyroid cancer is unclear, and the
subgroup of patients benefiting from it has still to be de-
fined.
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Introduction
It is well known that papillary thyroid carcinoma predom-
inantly metastasizes into regional lymph nodes [24]. In
cases with clinically or radiographically apparent lymph
node involvement, there is no debate about the prognostic
benefit of a neck dissection in addition to the total thy-
roidectomy [16, 24]. The management of nodal negative
tumors is still controversial. From “wait and see” as the
most conservative attitude to “node picking” or even pro-
phylactic neck dissection as the most aggressive option,
all suggestions are found in the current literature [4, 16,
24]. For the decision for or against prophylactic neck dis-
section in papillary thyroid carcinoma, the high incidence
(10–15%) of recurrent disease in the regional lymph nodes
[15, 18] and the impressive rate of occult nodal disease
(40–90%) [3, 19] found in elective neck dissections stand
in contrast to large scale studies that were not able to at-
tribute the status of an independent prognostic factor to
nodal involvement [13, 16, 24]. To date, there is no evi-
dence in the literature proving a general benefit of pro-
phylactic neck dissection for papillary thyroid cancer,
though some studies suggest a decrease of regional recur-
rence and improvement of survival for high risk patients
[6, 10, 14, 16, 21, 22, 23, 25, 29]. With regard to the lack
of data, the costs, the inconvenience for the patients and
the potential risks of this procedure, e.g., lesion of the re-
current laryngeal nerve during dissection of the central
compartment, most centers currently are favoring a con-
servative policy. Our policy for well-differentiated thyroid
cancer staged cN0 is not to dissect the cervical lymph
nodes as, based on the available data, we doubt that there
is any benefit of elective treatment for the patient in terms
of outcome.
The sentinel lymph node (SLN) concept has been suc-
cessfully introduced in the field of surgical oncology for
different tumors with predominantly nodal spread and high
risk for occult disease [1, 12, 17, 26, 28]. Analogously, for
papillary thyroid tumors the sentinel node biopsy has the
potential to identify and stage regional lymph node dis-
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ease without performing a prophylactic neck dissection.
Its accuracy and safety has been addressed in several stud-
ies by the use of a blue dye as a tracer, as well as in a few
trials using a radioisotope [2, 5, 7, 8, 11, 20]. Most proba-
bly, SLN biopsy will never achieve clinical relevance as a
standard treatment for all patients with thyroid papillary
cancer, but might play a role in a subgroup of high-risk
patients. As a center with a particular research interest and
experience in sentinel node biopsy, we had to define our
attitude towards this topic. In order to gain personal expe-
rience, we conducted a pilot study to assess the feasibility
and detect possible technical pitfalls of the preoperative
lymphatic mapping by lymphoscintigraphy and the sentinel
lymph node biopsy guided by the intraoperative use of a
hand-held gammaprobe in patients with uninodular thyroid
neoplasms.
Subjects and methods
The protocol of this study has been approved by the local Ethics
Committee, and the patients were entered into the study after they
had given written informed consent.
Patients with uninodular thyroid disease suspicious for malig-
nancy on fine-needle aspiration biopsy and no evidence of lymph
node disease as assessed by B-mode ultrasonography were eligible
for the study. Exclusion criteria were prior radiotherapy or surgery
in the neck, pregnancy or lactation.
The lymph node mapping was performed by preoperative lym-
phoscintigraphy and intraoperative use of a hand-held gammaprobe
(Neo 2000, Neoprobe Corporation, Dublin, Ohio). Patients under-
went lymphoscintigraphy 2 h before surgery. A sulfur colloid with
a particle size of 20 to 80 nm labeled with Technetium-99m
(Nanocoll, Nycomed Amershan, Sorin, Italy) was used for scintig-
raphy. Under ultrasound guidance one single injection of 20 MBq
in a volume of 0.2 ml normal saline was administered. According
to the technique used in mucosal squamous cell carcinoma [1, 26,
28] and malignant melanoma [17], we initially injected four peri-
tumoral spots of normal appearing thyroid tissue. As this technique
turned out to be very difficult and resulted in spillage of the radio-
tracer outside the thyroid, we changed the protocol and proceeded
with a single intratumoral injection. The lymphatic drainage was
monitored dynamically with a gamma camera (Siemens Diacam,
Germany) in the anteroposterior projection from the time of injec-
tion on until accumulation of the radiotracer in the SLN occurred.
Then, static imaging in both the anterioposterior and lateral views
were performed, and the location of the SLN was marked on the
patient’s skin surface.
In the operating room a formal hemithyroidectomy through a
low collar incision was performed to resect the nodule. The recur-
rent laryngeal nerve was monitored throughout the entire proce-
dure with intralaryngeal wire electrodes. No frozen sections of the
thyroid specimens were taken. With the aid of the gammaprobe the
central compartment was searched for hot spots through the cervi-
cal incision. The lateral compartments of the neck were bilaterally
scanned with the gammaprobe through the intact skin. Hot nodes
were selectively excised. The activity of the lymphatic bed had to
drop to background level after excision of the SLN(s). The loca-
tion of the SLN(s) was noted. No prophylactic neck dissection was
performed. The extensive histologic work-up of the SLN and the
description of occult metastases were carried out according to the
technique described in previous studies by Stoeckli et al. [27] and
Hermanek et al. [9]. All step-sections were stained for H and E and
cytokeratin.
Results
As approved by the local Ethics Committee, a total of ten
consecutive patients (eight females) with a mean age of
50 years (age range: 20–74 years) meeting the inclusion
criteria were prospectively enrolled in this pilot study.
In the first four patients, the radiotracer was injected
under ultrasound guidance in four peritumoral spots of
normal appearing thyroid tissue. In none of these cases
could a SLN be detected by lymphoscintigraphy. Intraop-
eratively, high levels of radioactivity were found in both
the thyroid lobe and the perithyroid muscular tissue, im-
peding detection of a SLN with the gammaprobe. There-
fore, the protocol was changed and the radiotracer injected
intratumorally in the remaining six cases. Out of these six
cases, lymphoscintigraphy was able to detect the SLN in
three patients (50%). With the aid of the gammaprobe, the
SLN was finally found in all six patients. The SLN was
located in the ipsilateral central compartment (level VI) in
three cases, and in the ipsilateral lateral compartment in
three cases, of which two were in level IV (near the jugu-
lar vein) and one in level II (the jugulodigastric node).
Lymphoscintigraphy correctly identified the SLN in level
II and two SLNs in the lower level VI. SLNs localized
very close to the thyroid tumor as the two SLNs in level
IV and one SLN in the upper level VI were missed by
lymphoscintigraphy. Three patients revealed three and the
other three only one SLN. In one of the latter patients, re-
maining radioactivity was detected with the gammaprobe
after excision of one SLN in the deep ipsilateral level VI.
This potential node could not be reached through the col-
lar incision and was left behind.
Histologic work-up of the thyroid specimens of the lat-
ter six patients revealed three patients with minimally in-
vasive follicular carcinoma, two with follicular adenoma
and one with a papillary carcinoma. One of the three SLNs
in the patient with a papillary carcinoma showed metasta-
tic disease (Fig. 1). All other SLNs were free of tumor.
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Fig. 1 Metastasis (∅ 4.2 mm) of a papillary thyroid carcinoma in
a SLN (×20; H and E stain). Inset: papilla with multinucleated giant
cell in center surrounded by lymphoid tissue (×250; H and E stain)
As to procedure-related complications, one patient ex-
perienced a temporary lesion of the recurrent laryngeal
nerve during dissection of the lower central compartment
for the search for a SLN. This patient recovered com-
pletely from hoarseness within 6 weeks, showing normal
vocal cord motility as assessed by direct laryngoscopy and
videostroboscopy at that time. No further intra- or postop-
erative complications occured.
Discussion
The aim of our pilot study was to assess the technical fea-
sibility of sentinel lymph node biopsy with a radiotracer
in patients presenting with uninodular thyroid disease sus-
picious for malignancy. As we were conducting a techni-
cal feasibility study for a procedure and not a clinical out-
come trial, not only patients with proven papillary carci-
nomas, but also a series of patients with uninodular thy-
roid neoplasms, were included. SLN biopsy has been in-
troduced in the field of malignant melanoma, breast can-
cer, oral squamous cell carcinoma and other tumors with
great reliability and accuracy [1, 12, 17, 26, 28]. It allows
the histological staging of the lymphatic drainage without
excising the whole lymphatic basin. By doing this, pa-
tients who benefit from extended lymphatic dissection can
be selected, and the others can be spared the risks and costs
of this procedure. In contrast to most other malignancies
with preferentially lympatic spread, the stage of lymph
node involvement seems not to be a general prognostica-
tor in differentiated thyroid cancer [4, 16, 24]. Therefore,
we can not expect any benefit with regard to survival from
disclosing occult metastatic neck disease by SLN biopsy
in all patients. However, more recent studies have come up
demonstrating an elevated regional failure rate and prog-
nostic impact of neck metastases in a subset of high-risk
patients [6, 10, 14, 16, 21, 22, 23, 25, 29]. Unfortunately,
all these studies only address palpable or imaging-detectable
lymph nodes or macrometastatic disease as discovered by
neck dissection. The impact of occult metastatic lymph
node involvement on recurrence and survival has not yet
been elucidated prospectively. The question still remains:
is a cN0 neck that turns out to be a pN+ (mi) (sn) [9] neck
rather comparable to a pN0 neck or to a pN+ neck? Or, in
other words, is occult metastatic lymph node disease in
high-risk groups an independent prognosticator that should
be therapeutically addressed? Though the high-risk cohort
of patients with advanced age, gross tumor extent, distant
metastases or large tumor size might be the group to study
for a potential benefit of SLN biopsy, the trial to resolve
this question is very unlikely to succeed. With regard to
the high cure rate and the slow growing pattern of papil-
lary thyroid cancer, the number of patients and the dura-
tion of such a study probably exceeds by far what is feasi-
ble. Further, occult metastases as an independent prognos-
ticator would have to compete in this high-risk setting
with all the aforementioned strong prognosticators. In con-
clusion, we think that the benefit of SLN biopsy is hard to
prove, but it could be the way to go for those who believe
in prophylactic neck dissections in papillary thyroid can-
cer.
Most previous studies used the intraoperative injection
of a blue dye to trace the lymphatics to the SLN [2, 7, 8,
11]. There are several disadvantages of this technique.
First of all, lymphatics that run out of the central com-
partment can not be followed through the collar incision
for thyroidectomy. Further, dissection of the thyroid node
for injection, even if done very gently, bares the risk of in-
terrupting important lymphatic vessels, and finally, to rec-
ognize a node as being blue is not always that easy. To
overcome these drawbacks in our study we used a preop-
erative ultrasound guided injection of a radiocolloid in-
stead of a blue dye to trace the SLN. The combination of
lymphoscintigraphy and the intraoperative use of a hand-
held gammaprobe were used to localize the SLN. This
technique allows the assessment of the entire neck and
mediastinum, and all the surgical dissection is done after
accumulation of the tracer in the SLN. The sensitivity of
lymphoscintigraphy turned out to be only 50%. This result
is in agreement with the findings of two previous studies
[5, 20], which both reported a sensitivity of lymphoscintig-
raphy of 66%. In contrast to other entities like malignant
melanoma, breast carcinoma or squamous cell carcinoma
of the oral cavity, lymphscintigraphy seems not to be
equally successful in SLN biopsy for thyroid malignan-
cies. But, all the SLNs missed by lymphoscintigraphy
were very close to the injection site and most probably
hidden behind the thyroid in the paratracheal space. In
contrast, all distant SLNs (lateral compartment or lower
central compartment) were adequately revealed. Therefore,
the role for lymphoscintigraphy is mainly to address SLNs
that might not be localized in the vicinity of the thyroid
tumor. SLNs close to the primary are easily detected with
the gammaprobe after removal of the thyroid. The infor-
mation about the need to extend the skin incision or even
to perform additional skin incisions for nodes in the lateral
compartments or about the increased risk of nerve damage
during the search for nodes in the lower central compart-
ment are crucial for the patient and the surgeon. It is al-
ways much easier to handle the gammaprobe when the sur-
geon has a rough idea where to look for the SLN. There-
fore, despite the low overall sensitivity, we still recom-
mend the performance of preoperative lymphoscintigraphy.
In order to perform lymphoscintigraphy we injected
the radiotracer preoperatively under ultrasound guidance.
The initial attempt to inject four spots of healthy tissue
around the tumor as suggested for all other cancers showed
up to be detrimental because of spillage of the colloid into
the surrounding tissue, impeding any further evaluation.
According to the published studies [2, 5, 7, 11, 20, 27]
about SLN biopsy for thyroid cancer, we changed our pro-
tocol and continued with direct intratumoral injections.
This technique worked out very well, and with the aid of
the handheld gammaprobe the detection and excision of
the SLN was possible in all remaining cases.
In conclusion, where lymphatic mapping is concerned,
the combination of preoperative lymphoscinitigraphy and
intraoperative gammaprobe is recommended. The injec-
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tion of the radiotracer should be intratumoral and is best
performed preoperatively under ultrasound guidance. With
regard to the good results reported with the use of a blue
dye, the combination of a radiotracer and a blue dye might
enhance the identification rate of the SLN [5].
Irrespective of the localization techniques, the excision
of all SLNs was not always possible. In one particular case
a second SLN was detected with the gammaprobe deep in
the fatty tissue of the retrosternal central compartment.
Excision of this node was not possible through the low
collar approach so that it had to be left behind. This prob-
lem was also encountered by Kelemen et al. [11] and Dixon
et al. [7]. In their studies the blue staining lymphatics ran
to the mediastinum in 2 out of 17, and 2 out of 40 patients,
respectively, impeding the excision of these SLNs.
As to procedure-related complications in our series,
one patient experienced a temporary lesion of the recurrent
laryngeal nerve. Intraoperative nerve stimulation proved
the nerve to be intact after thyroidectomy. Exploration of
the lower central compartment for a SLN caused bleeding
from a small blood vessel, which was controlled by bipo-
lar cautery. After this maneuvre the answers of the recur-
rent laryngeal nerve to the nerve stimulator were lost. We
assume that the nerve underwent thermal damage during
coagulation. These cases illustrate that the SLN of a thy-
roid cancer can be located in the lower central compart-
ment and that its excision might be difficult or even im-
possible in some cases and bare the risk of injuring the re-
current laryngeal nerve.
Even in our small series with only one thyroid nodule
turning out to be a papillary cancer, occult metastatic dis-
ease of the considerable size of 4.2 mm in diameter was
disclosed by sentinel node biopsy, underlining the poten-
tial of this technique.
With regard to the results of the currently available stud-
ies about SLN biopsy in differentiated thyroid cancer, it
can be stated that this technique is feasible with a high
chance of detecting the SLN. The accuracy as elucidated
by studies performing neck dissections after SLN biopsy
is also fairly high [2, 8, 11]. Centers favoring prophylactic
treatment of the lymph nodes in papillary thyroid cancer
patients might think about performing SLN biopsy to re-
duce the number of unnecessary neck dissections.
Though technically feasible and a minor procedure, in
our opinion SLN biopsy remains an overtreatment for N0
papillary carcinoma, unless a subset of high-risk patients
is defined that will benefit from elective neck treatment in
terms of survival. The SLN concept works out well only
in tumors in which detection and treatment of lymph node
metastases has an impact on outcome. With regard to this
and the potential risks of the procedure we will not change
our current policy.
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